Business Description
Vistagen Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92840H2022
Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.8 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 15.8 | |||||
| 3-Year EPS without NRI Growth Rate | 17.2 | |||||
| 3-Year FCF Growth Rate | 12.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.18 | |||||
| 9-Day RSI | 73.04 | |||||
| 14-Day RSI | 67.82 | |||||
| 6-1 Month Momentum % | 21.74 | |||||
| 12-1 Month Momentum % | -13.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.43 | |||||
| Quick Ratio | 13.43 | |||||
| Cash Ratio | 12.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -64.6 | |||||
| Shareholder Yield % | -221.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4406.9 | |||||
| Net Margin % | -4369.34 | |||||
| FCF Margin % | -3879.31 | |||||
| ROE % | -169.18 | |||||
| ROA % | -119.27 | |||||
| ROIC % | -670.42 | |||||
| ROC (Joel Greenblatt) % | -1290.22 | |||||
| ROCE % | -140.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 45.15 | |||||
| PB Ratio | 1.57 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| EV-to-EBIT | -2.54 | |||||
| EV-to-EBITDA | -2.58 | |||||
| EV-to-Revenue | 111.36 | |||||
| EV-to-Forward-Revenue | 137.87 | |||||
| EV-to-FCF | -2.87 | |||||
| Price-to-Net-Current-Asset-Value | 1.72 | |||||
| Price-to-Net-Cash | 1.8 | |||||
| Earnings Yield (Greenblatt) % | -39.37 | |||||
| FCF Yield % | -25.07 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VTGN
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vistagen Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.812 | ||
| EPS (TTM) ($) | -4.709 | ||
| Beta | 0.62 | ||
| Volatility % | 265.85 | ||
| 14-Day RSI | 67.82 | ||
| 14-Day ATR ($) | 0.368756 | ||
| 20-Day SMA ($) | 3.64875 | ||
| 12-1 Month Momentum % | -13.73 | ||
| 52-Week Range ($) | 1.62 - 24.71 | ||
| Shares Outstanding (Mil) | 27.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vistagen Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vistagen Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vistagen Therapeutics Inc Frequently Asked Questions
What is Vistagen Therapeutics Inc(VTGN)'s stock price today?
The current price of VTGN is $4.65. The 52 week high of VTGN is $24.71 and 52 week low is $1.62.
When is next earnings date of Vistagen Therapeutics Inc(VTGN)?
The next earnings date of Vistagen Therapeutics Inc(VTGN) is 2024-02-07 Est..
Does Vistagen Therapeutics Inc(VTGN) pay dividends? If so, how much?
Vistagen Therapeutics Inc(VTGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers